Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.

Background

Endometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the introduction of dostarlimab in microsatellite instability (MSI) high pre-treated advanced EC patients with further expected innovation deriving from lenvatinib plus pembrolizumab regardless MSI status. How this is and will be translated and embedded in the clinical setting in Italy is not known; this is why we developed Multicentre Italian Trials in Ovarian cancer and gynaecologic malignancies (MITO) survey on the current practice and expected future changes in EC.

Methods

We designed a self-administered, multiple-choice online questionnaire available only for MITO members for one month, starting in April 2021.

Results

75.6% of the respondents were oncologists with a specific focus on gynaecologic malignancies and 73.3% of the respondents declared the availability of clinical trials in second line treatment for advanced EC. The therapeutic algorithm in second line was heterogeneous, being the most frequent choice administering anthracyclines followed by endocrine therapy or enrolling in clinical trials. While more than half of the clinicians declared that they performed the molecular classification, only six/45 respondents (13.3%) ran all the tests needed for it. On the other hand, 80% of them declared regular assessment of MSI status with IHC as recommended. The therapeutic approach in MSI high advanced EC patients has changed since dostarlimab approval. Indeed the most frequent choice in second line has been chemotherapy (53.3%) before its availability, while dostarlimab has been preferred in more than three-fourths of the cases (75.6%) after its approval. As for MSS patients, 77.8% of clinicians would choose lenvatinib plus pembrolizumab for them in second line once approved.

Conclusions

Despite the selected sample of respondents from Italian MITO centres showing good knowledge of diagnostic and therapeutic innovations in EC, these are not fully implemented in everyday clinics, except for MSI status assessment.

Informations de copyright

Copyright © 2022 Giannone, Castaldo, Tuninetti, Scotto, Turinetto, Valsecchi, Bartoletti, Mammoliti, Artioli, Mangili, Salutari, Lorusso, Cormio, Zamagni, Savarese, Di Maio, Ronzino, Pisano, Pignata and Valabrega.

Déclaration de conflit d'intérêts

GG received a grant from ESMO and payment for educational events from Mylan, she coordinates MITO Gruppo Formazione. DL received grants or contracts from GSK, MSD, Clovis Oncology, consulting fees from Pharmamar, Merck Serono, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK, Clovis Oncology, Astra Zeneca, MSD; payment for expert testimony from Clovis Oncology; support for attending meetings and/or travel from GSK, Roche, Pharmamar; participation on a Data Safety Monitoring Board or Advisory Board for Novartis, Seagen, MSD, Astra Zeneca, Immunogen, Genmab, Amgen, Clovis Oncology, GSK, Merck Serono and she is Chair of Gynecological Cancer Accademy, Bord of Director of Gynecological cancer Integroup. MDM received Grants or contracts to his institution from Tesaro and GSK, consulting fees from Novartis, Roche, AstraZeneca, Merck Serono, Pfizer, Merck Sharp & Dohme, Janssen, Eisai, Takeda, Boehringer Ingelheim, Servier; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Roche, AstraZeneca, Pfizer, Merck Sharp & Dohme, Janssen, Astellas, Boehringer Ingelheim; Participation on a Data Safety Monitoring Board or Advisory Board for Merck Sharp & Dohme, Janssen, Astellas and Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.